{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:33:34Z","timestamp":1790937214995,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.2515\/therapie:2006048","type":"journal-article","created":{"date-parts":[[2007,4,19]],"date-time":"2007-04-19T10:59:53Z","timestamp":1176980393000},"page":"195-199","source":"Crossref","is-referenced-by-count":6,"title":["Antifongiques : cibles cellulaires et m\u00e9canismes de r\u00e9sistance"],"prefix":"10.1016","volume":"61","author":[{"given":"Isabelle","family":"Accoceberry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"No\u00ebl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.2515\/therapie:2006048_bb0010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S1473-3099(02)00181-0","article-title":"Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences","volume":"2","author":"Sanglard","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"10.2515\/therapie:2006048_bb0015","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1128\/AAC.48.6.2223-2227.2004","article-title":"Clade-specific flucytosine resistance is due to a single nucleotide change in the FUR1 gene of Candida albicans","volume":"48","author":"Dodgson","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie:2006048_bb0020","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1128\/AAC.47.4.1213-1219.2003","article-title":"Genetic basis for differential activities of fluconazole and voriconazole against Candida krusei","volume":"47","author":"Fukuoka","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie:2006048_bb0025","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/jac\/46.2.171","article-title":"Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions","volume":"46","author":"Vermes","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.2515\/therapie:2006048_bb0030","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1128\/AAC.49.8.3101-3108.2005","article-title":"Inactivation of the FCY2 gene encoding purine-cytosine permease promotes cross-resistance to flucytosine and fluconazole in Candida lusitaniae","volume":"49","author":"Chapeland-Leclerc","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie:2006048_bb0035","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1128\/AAC.48.4.1136-1144.2004","article-title":"The Candida albicans lanosterol 14- alpha-demethylase (ERG11) gene promoter is maximally induced after prolonged growth with antifungal drugs","volume":"48","author":"Song","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie:2006048_bb0040","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1128\/AAC.41.10.2229","article-title":"Molecular biological characterization of an azole-resistant Candida glabrata isolate","volume":"41","author":"Marichal","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie:2006048_bb0045","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1073\/pnas.061562898","article-title":"Crystal structure of cytochrome P450 14alpha-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors","volume":"98","author":"Podust","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.2515\/therapie:2006048_bb0050","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1128\/AAC.39.11.2378","article-title":"Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters","volume":"39","author":"Sanglard","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie:2006048_bb0055","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/BF00352101","article-title":"Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals","volume":"27","author":"Prasad","year":"1995","journal-title":"Curr Genet"},{"key":"10.2515\/therapie:2006048_bb0060","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1099\/00221287-143-2-405","article-title":"Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene","volume":"143","author":"Sanglard","year":"1997","journal-title":"Microbiology"},{"key":"10.2515\/therapie:2006048_bb0065","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1365-2958.2003.03430.x","article-title":"The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin","volume":"48","author":"Schuetzer-Muehlbauer","year":"2003","journal-title":"Mol Microbiol"},{"key":"10.2515\/therapie:2006048_bb0070","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1128\/EC.3.6.1639-1652.2004","article-title":"TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2","volume":"3","author":"Coste","year":"2004","journal-title":"Eukaryot Cell"},{"key":"10.2515\/therapie:2006048_bb0075","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1128\/AAC.48.12.4505-4512.2004","article-title":"CaNdt80 is involved in drug resistance in Candida albicans by regulating CDR1","volume":"48","author":"Chen","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie:2006048_bb0080","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.bbrc.2005.04.113","article-title":"Expression of the CDR1 efflux pump in clinical Candida albicans isolates is controlled by a negative regulatory element","volume":"332","author":"Gaur","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.2515\/therapie:2006048_bb0085","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1128\/AAC.47.9.2717-2724.2003","article-title":"Disruption of ergosterol biosynthesis confers resistance to amphotericin B in Candida lusitaniae","volume":"47","author":"Young","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie:2006048_bb0090","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0378-1119(95)00770-9","article-title":"Cloning and characterization of the Saccharomyces cerevisiae C-22 sterol desaturase gene, encoding a second cytochrome P-450 involved in ergosterol biosynthesis","volume":"169","author":"Skaggs","year":"1996","journal-title":"Gene"},{"key":"10.2515\/therapie:2006048_bb0095","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1574-6968.1994.tb07140.x","article-title":"Resistance to amphotericin B associated with defective sterol delta 8-7 isomerase in a Cryptococcus neoformans strain from an AIDS patient","volume":"122","author":"Kelly","year":"1994","journal-title":"FEMS Microbiol Lett"},{"key":"10.2515\/therapie:2006048_bb0100","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0140-6736(05)65949-1","article-title":"Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients","volume":"348","author":"Kelly","year":"1996","journal-title":"Lancet"},{"key":"10.2515\/therapie:2006048_bb0105","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1128\/AAC.41.1.196","article-title":"Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia","volume":"41","author":"Nolte","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie:2006048_bb0110","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0140-6736(03)14472-8","article-title":"Echinocandin antifungal drugs","volume":"362","author":"Denning","year":"2003","journal-title":"Lancet"},{"key":"10.2515\/therapie:2006048_bb0115","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1128\/AAC.41.11.2471","article-title":"Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors","volume":"41","author":"Douglas","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie:2006048_bb0120","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1128\/AAC.48.1.319-322.2004","article-title":"FKS1 mutations responsible for selective resistance of Saccharomyces cerevisiae to the novel 1,3-beta-glucan synthase inhibitor arborcandin C","volume":"48","author":"Ohyama","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie:2006048_bb0125","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1128\/AAC.48.10.3871-3876.2004","article-title":"Genomic approach to identification of mutations affecting caspofungin susceptibility in Saccharomyces cerevisiae","volume":"48","author":"Markovich","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie:2006048_bb0130","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1128\/AAC.46.8.2462-2469.2002","article-title":"Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccharomyces cerevisiae","volume":"46","author":"Osherov","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie:2006048_bb0135","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1128\/JCM.40.3.852-856.2002","article-title":"Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000","volume":"40","author":"Pfaller","year":"2002","journal-title":"J Clin Microbiol"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004059571630395X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004059571630395X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T03:00:16Z","timestamp":1554260416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004059571630395X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S004059571630395X"],"URL":"https:\/\/doi.org\/10.2515\/therapie:2006048","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}